182 related articles for article (PubMed ID: 36080360)
21. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
22. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47.
Hatherley D; Graham SC; Turner J; Harlos K; Stuart DI; Barclay AN
Mol Cell; 2008 Jul; 31(2):266-77. PubMed ID: 18657508
[TBL] [Abstract][Full Text] [Related]
23. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
[TBL] [Abstract][Full Text] [Related]
24. Biomimetic Design of Peptide Inhibitor to Block CD47/SIRPα Interactions.
Zheng S; Ji Y; Li N; Zhang L
Langmuir; 2023 Dec; 39(49):18101-18112. PubMed ID: 38038444
[TBL] [Abstract][Full Text] [Related]
25. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
26. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.
Seiffert M; Brossart P; Cant C; Cella M; Colonna M; Brugger W; Kanz L; Ullrich A; Bühring HJ
Blood; 2001 May; 97(9):2741-9. PubMed ID: 11313266
[TBL] [Abstract][Full Text] [Related]
27. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
28. Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
Fournier B; Andargachew R; Robin AZ; Laur O; Voelker DR; Lee WY; Weber D; Parkos CA
J Biol Chem; 2012 Jun; 287(23):19386-98. PubMed ID: 22511785
[TBL] [Abstract][Full Text] [Related]
29. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
30. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
31. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
32. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
33. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
34. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
35. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
36. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
37. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy.
Huang B; Bai Z; Ye X; Zhou C; Xie X; Zhong Y; Lin K; Ma L
Comput Struct Biotechnol J; 2021; 19():5494-5503. PubMed ID: 34712395
[TBL] [Abstract][Full Text] [Related]
38. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
40. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
Weiskopf K; Ring AM; Ho CC; Volkmer JP; Levin AM; Volkmer AK; Ozkan E; Fernhoff NB; van de Rijn M; Weissman IL; Garcia KC
Science; 2013 Jul; 341(6141):88-91. PubMed ID: 23722425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]